Jefferies Starts Oruka Therapeutics (ORKA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St advances on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices sink, shrugging off renewed Middle East fighting
- ASML capacity upgrade soothes AI chip bottleneck fears
TD Cowen Starts Oruka Therapeutics (ORKA) at Buy
September 16, 2024 5:31 AM EDTTD Cowen analyst Tyler Van Buren initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating.
The analyst comments "Oruka is backed by sophisticated mAb engineering and both ORKA-001 and ORKA-002 have a high PoS by targeting the same... More
Oruka Therapeutics (ORKA) Announces $200 Million Private Placement
September 12, 2024 7:05 AM EDTOruka Therapeutics, Inc. (Oruka or the Company) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including a large investment manager, Braidwell LP, Venrock Healthcare Capital Partners, Fairmount, Access Biotechnology, Blackstone... More
Oruka Therapeutics (ORKA) Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile
September 12, 2024 7:01 AM EDTOruka Therapeutics, Inc. (Oruka) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced updated pipeline progress and timelines, as well as an upcoming scientific presentation at the European Academy of Dermatology and Venereology Congress (EADV).
First-in-human dosing of ORKA-001 in healthy volunteers is now expected to start during the first quarter of 2025. ORKA-001 is a novel, subcutaneously (SQ) administered, half-life extended mAb targeting IL-23p19. Inhibitors... More
